Article

The Evolving Role of PI3K Inhibitors in the Treatment of Follicular Lymphoma

On June 18, 2021, OncLive® brought together a group of oncologists who specialize in the treatment of follicular lymphoma to participate in a virtual workshop to discuss the evolving role of PI3K inhibitors in the treatment of follicular lymphoma. This article summarizes key data about PI3K inhibitors as a therapeutic target as well as insights from stakeholder discussions regarding this topic.

Related Videos
Sarah Sammons, MD
Laura Spring, MD
Laura Spring, MD
Corey J. Langer, MD
John F. Lazar, MD
Rodolfo Bordoni, MD
Brad S. Kahl, MD, of Siteman Cancer Center
John P. Leonard, MD, of Weill Cornell Medicine
John P. Leonard, MD, of Weill Cornell Medicine